FindTrial
Sign In

Key factors for response in the treatment of liver metastatic melanoma by cryoablation combined with PD-1 blockade therapy: the Cryo-Fire-001 study

Key factors for response in the treatment of liver metastatic melanoma by cryoablation combined with PD-1 blockade therapy: the Cryo-Fire-001 study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300069319
Enrollment
Unknown
Registered
2023-03-13
Start date
2023-03-13
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Melanoma

Interventions

Observation Group:Cryoablation combined with PD-1 blockade therapy

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Histological diagnosis of melanoma; 2. With multiple liver metastasis; 3. Received cryoablation of liver metastases within one week of PD-1 blockade therapy; 4. Performance score 0 or 1 based on the Eastern Cooperative Oncology Group (ECOG) Performance Scale; 5. No active or a documented history of autoimmune disease; 6. Life expectancy more than three months.

Exclusion criteria

Exclusion criteria: 1. Received PD-1 blockade therapy before identification of liver metastases; 2. With other malignancies.

Design outcomes

Primary

MeasureTime frame
Overall Survival;—

Secondary

MeasureTime frame
Objective Response Rate;Adverse reactions and serious adverse events;—

Countries

China

Contacts

Public ContactWeijun Fan

Sun Yat-sen University Cancer Center

fanwj@sysucc.org.cn+86 13826154530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026